Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Pharmaceutical Equivalents

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Quality guidelines for radiopharmacy: Development of a risk-assessment tool].

Annales pharmaceutiques francaises·2021

Same author

[Use of radiopharmaceuticals in pediatrics: Specificities and recommandations of SoFRa (Société française de radiopharmacie)].

Annales pharmaceutiques francaises·2020

Same author

Using bone marrow matrix to analyze meprobamate for forensic toxicological purposes.

International journal of legal medicine·2013

Same author

Gas chromatography-tandem mass spectrometry assay for the quantification of four benzodiazepines and citalopram in eleven postmortem rabbit fluids and tissues, with application to animal and human samples.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2011

Same author

Postmortem measurement of caffeine in bone marrow: influence of sample location and correlation with blood concentration.

Forensic science international·2011

Same author

Kienböck's disease and cerebral palsy case report.

Annals of physical and rehabilitation medicine·2009

Search research articles

Related Experiment Video

Updated: Jan 2, 2026

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

[What do we expect from Radiopharmacy software?]

S Blondeel-Gomes¹, D Peyronnet², C Le Meur³

¹Département de radiopharmacologie, Institut Curie, 26, rue d'Ulm, 75005 Paris, France.

Annales Pharmaceutiques Francaises

|December 5, 2019

Summary

Computerizing the Radiopharmaceutical Health Products (RHP) circuit enhances efficiency and traceability. New specifications address unique radiopharmacy needs, guiding software development for better RHP management.

Keywords:

Logiciel Médecine nucléaire Médicaments radiopharmaceutiques Nuclear Médicine Nuclear pharmacy Radiopharmaceuticals Radiopharmacie Software

More Related Videos

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Published on: April 11, 2018

Optimization of Radiochemical Reactions using Droplet Arrays

Optimization of Radiochemical Reactions using Droplet Arrays

Published on: February 12, 2021

Related Experiment Videos

Last Updated: Jan 2, 2026

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System

Published on: April 11, 2018

Optimization of Radiochemical Reactions using Droplet Arrays

Optimization of Radiochemical Reactions using Droplet Arrays

Published on: February 12, 2021

Area of Science:

Radiopharmacy
Health Informatics
Regulatory Compliance

Background:

The Radiopharmaceutical Health Products (RHP) circuit involves complex processes for radiopharmaceutical drugs, preparations, and radioactive medical devices.
Current RHP circuits require computerization for efficiency and adherence to medicinal product and artificial radioelement legislation.
Existing software solutions lack specific legislation, not being classified as medical devices or prescription/dispensation aids.

Purpose of the Study:

To establish a minimum set of specifications for radiopharmaceutical software products.
To address the unique requirements of radiopharmacy within the RHP circuit.
To guide software publishers in developing tools tailored for radiopharmaceutical practices.

Main Methods:

A working group under the Société Française de Radiopharmacie (SoFRa) developed the specifications.
Analysis of risk maps from various hospital structures informed the global synthesis of processes, settings, interfaces, and requirements.
Incorporation of specific radiopharmacy needs, including radioactive decay, complex chemical synthesis, and traceability.

Main Results:

A comprehensive set of specifications for radiopharmaceutical software has been created.
The specifications cover unique radiopharmacy considerations like radioactive decay and traceability.
These guidelines will facilitate the development of adapted software tools for the RHP circuit.

Conclusions:

Standardized software specifications are crucial for the effective computerization of the RHP circuit.
The developed specifications ensure that software meets the specialized demands of radiopharmacy.
This initiative will lead to improved tools for managing radiopharmaceutical processes and enhancing patient safety.